gastroesophageal junction adenocarcinomas
Keytruda Receives Traditional Approval for Some Patients With HER2-Positive Gastric or GEJ Adenocarcinoma
The FDA has approved pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the ...
MARCH 28, 2025
Tevimbra Approved for Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemo
The FDA has approved tislelizumab in combination with chemotherapy for the first-line treatment of unresectable or ...
JANUARY 15, 2025
Vyloy With Chemotherapy Approved for Gastric or Gastroesophageal Junction Adenocarcinoma
The FDA has approved zolbetuximab for the first-line treatment of adults with advanced gastric or gastroesophageal ...
NOVEMBER 4, 2024
FDA Amends Keytruda’s Gastric Cancer Indication
On Nov. 7, 2023, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab-, ...
NOVEMBER 14, 2023
Load more